Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBoston Scientific Corp

Boston Scientific Corp

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
43.5 USD -0.82 ( 1.85%)
Last update at 2026-11-03T21:03:00Z
VOLUME
18745663
Market Cap
63577.70M
P/E
18.28

Momentum Score

…

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
43.21
Low
44.62
High
52 Week Price Range
42.20
Low
105.65
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Boston Scientific is a global medical device company that develops and sells products for cardiovascular, rhythm management, endoscopy, urology, neuromodulation and peripheral interventions; long-term growth may be supported by an aging population, greater adoption of minimally invasive procedures, ongoing product launches and geographic expansion. Investors may find the company attractive because of a diversified procedure-driven portfolio, recurring consumables demand and an active R&D and acquisition strategy that could support sustained revenue streams.

Key risks include regulatory and reimbursement changes, intense competition, product liability exposure and execution challenges such as acquisition integration and supply-chain disruptions that could pressure growth and margins.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
44.32
Dividend Yield
-
Revenue TTM
20996.00M
Revenue Per Share
14.19
Gross Profit TTM
14527.00M
Debt / Equity
0.51
ROE
15.34%
Net Debt
10373.00M
ROCE
10.39%
Diluted EPS TTM
2.40

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 3385.00M 2282.00M 1985.00M 1141.00M 1076.00M
Minority interest 6.00M 8.00M 1.00M - -
Net income 2886.00M 1854.00M 1593.00M 698.00M 1041.00M
Selling general administrative 6887.00M 5984.00M 4974.00M 4520.00M 4359.00M
Gross profit 13853.00M 10267.00M 8831.00M 8679.00M 8128.00M
Reconciled depreciation 1368.00M 1269.00M 1177.00M 803.00M 741.00M
Ebit - 2669.00M 2257.00M 1649.00M 2043.00M
Ebitda 3733.00M 3938.00M 3453.00M 2800.00M 2784.00M
Depreciation and amortization - 1269.00M 1196.00M 1151.00M 741.00M
Non operating income net other - - - -38.00M 218.00M
Operating income 3971.00M 2635.00M 2181.00M 1649.00M 2043.00M
Other operating expenses 16103.00M 14112.00M 12059.00M 10649.00M 10064.00M
Interest expense 349.00M 387.00M 272.00M 470.00M 341.00M
Tax provision 493.00M 436.00M 647.00M 443.00M 36.00M
Interest income 349.00M 107.00M 22.00M 470.00M 341.00M
Net interest income -320.00M -198.00M -254.00M -470.00M -341.00M
Non recurring - - - 376.00M 889.00M
Income tax expense 493.00M 436.00M 393.00M 443.00M 36.00M
Total revenue 20074.00M 16747.00M 14240.00M 12682.00M 11888.00M
Total operating expenses 9882.00M 7632.00M 6650.00M 6646.00M 6304.00M
Cost of revenue 6221.00M 6480.00M 5409.00M 4003.00M 3760.00M
Total other income expense net -586.00M -353.00M -196.00M -508.00M -967.00M
Net income from continuing ops 2892.00M 1846.00M 1228.00M 698.00M 1041.00M
Net income applicable to common shares 2898.00M 1853.00M 1570.00M 642.00M 986.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 43673.00M 39395.00M 35136.00M 32470.00M 32230.00M
Intangible assets 7019.00M 6684.00M 6003.00M 5903.00M 6120.00M
Other current assets 879.00M 1138.00M 937.00M 350.00M 385.00M
Total liab 19201.00M 17392.00M 15606.00M 14896.00M 15607.00M
Total stockholder equity 24233.00M 21770.00M 19282.00M 17574.00M 16623.00M
Deferred long term liab - - - 144.00M 310.00M
Other current liab 3294.00M 3048.00M 2974.00M 2701.00M 3011.00M
Common stock 17.00M 17.00M 17.00M 17.00M 17.00M
Capital stock 17.00M 17.00M 17.00M 17.00M 17.00M
Retained earnings 5571.00M 2673.00M 819.00M -750.00M -1392.00M
Other liab - - - 1831.00M 2140.00M
Good will 18282.00M 17089.00M 14387.00M 12920.00M 11988.00M
Other assets 5077.00M -1.00M 1.00M -1.00M 2.00M
Cash 2045.00M 414.00M 865.00M 928.00M 1925.00M
Cash and equivalents 1965.00M 414.00M 865.00M 928.00M 1925.00M
Total current liabilities 5439.00M 6399.00M 4933.00M 3803.00M 4274.00M
Current deferred revenue 313.00M 306.00M 266.00M 220.00M 208.00M
Net debt 10373.00M 10733.00M 8627.00M 8354.00M 7526.00M
Short term debt 389.00M 1778.00M 531.00M 20.00M 261.00M
Short long term debt 299.00M 1778.00M 531.00M 20.00M 261.00M
Short long term debt total 12418.00M 11147.00M 9492.00M 9282.00M 9451.00M
Other stockholder equity 19255.00M 18805.00M 18397.00M 18038.00M 17735.00M
Property plant equipment 4501.00M 3743.00M 3298.00M 2832.00M 2252.00M
Total current assets 8794.00M 6920.00M 6514.00M 5760.00M 6317.00M
Long term investments - 555.00M 413.00M 407.00M 412.00M
Net tangible assets - - - 11670.00M -1723.00M
Net receivables 2926.00M 2558.00M 2228.00M 1970.00M 1778.00M
Long term debt 11137.00M 8842.00M 8566.00M 8915.00M 8795.00M
Inventory 2944.00M 2810.00M 2484.00M 1867.00M 1610.00M
Accounts payable 1144.00M 960.00M 942.00M 862.00M 794.00M
Accumulated other comprehensive income -610.00M 275.00M 49.00M 269.00M 263.00M
Common stock total equity - - - 17.00M 17.00M
Retained earnings total equity - - - -750.00M -1392.00M
Treasury stock - - - -2251.00M -2251.00M
Non currrent assets other 559.00M 749.00M 680.00M 707.00M 563.00M
Non current assets total 34879.00M 32476.00M 28622.00M 26710.00M 25911.00M
Capital lease obligations 125.00M 527.00M 395.00M 352.00M 395.00M
Long term debt total 11137.00M 8968.00M 8571.00M 8915.00M 8804.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -5687.00M -1704.00M 56.00M 15.00M
Change to liabilities - - - -255.00M 408.00M
Total cashflows from investing activities -2640.00M -5687.00M -2574.00M -2011.00M -1597.00M
Net borrowings -491.00M 1827.00M -4.00M -165.00M -165.00M
Total cash from financing activities -395.00M 1814.00M 5.00M -548.00M -95.00M
Change to operating activities - - - -209.00M -134.00M
Net income 2892.00M 1846.00M 1592.00M 698.00M 1041.00M
Change in cash 1541.00M -449.00M -82.00M -1042.00M 173.00M
Begin period cash flow 606.00M 1055.00M 1077.00M 2168.00M 1995.00M
End period cash flow 2147.00M 606.00M 995.00M 1126.00M 2168.00M
Total cash from operating activities 4534.00M 3435.00M 2503.00M 1526.00M 1870.00M
Issuance of capital stock - - - 0.00M 0.00M
Depreciation 1368.00M 1269.00M 1196.00M 1136.00M 1093.00M
Other cashflows from investing activities -171.00M -257.00M -52.00M -1423.00M -1057.00M
Dividends paid - 0.00M 28.00M -55.00M -55.00M
Change to inventory -188.00M -228.00M -660.00M -321.00M -346.00M
Change to account receivables -269.00M -351.00M -238.00M -220.00M -279.00M
Sale purchase of stock 282.00M 230.00M 182.00M 136.00M 110.00M
Other cashflows from financing activities -186.00M -243.00M -145.00M 2806.00M -150.00M
Change to netincome - - - 410.00M 100.00M
Capital expenditures 876.00M 790.00M 800.00M 612.00M 554.00M
Change receivables - - - -220.00M -279.00M
Cash flows other operating - - - 79.00M -146.00M
Cash and cash equivalents changes - - - -1033.00M 178.00M
Change in working capital -246.00M -462.00M -770.00M -1005.00M -351.00M
Stock based compensation 299.00M 266.00M 233.00M 220.00M 194.00M
Other non cash items 221.00M 516.00M 253.00M 540.00M 17.00M
Free cash flow 3658.00M 2645.00M 1703.00M 914.00M 1316.00M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BSX
Boston Scientific Corp		 -0.82
1.85%		 43.50 18.28 13.24 3.03 2.62 3.69 13.73
ABT
Abbott Laboratories		 -
-%		 109.40 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -0.41
0.41%		 98.88 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 3.74
1.22%		 310.55 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 0.66
1.38%		 48.35 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Boston Scientific Corp

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234

508 683 4000

https://www.bostonscientific.com

59000

Name Title Year Born
Mr. Michael F. Mahoney Chairman, Pres & CEO 1965
Mr. Daniel J. Brennan Exec. VP & CFO 1966
Mr. Joseph M. Fitzgerald Exec. VP & Group Pres of Cardiology 1964
Mr. Jeffrey B. Mirviss Exec. VP & Pres of Peripheral Interventions 1966
Mr. John Bradley Sorenson Exec. VP of Global Operations 1968
Mr. Jonathan R Monson VP, Global Controller & Chief Accounting Officer NA
Ms. Jodi Euerle Eddy Sr. VP and Chief Information & Digital Officer 1973
Ms. Susan Vissers Lisa VP of Investor Relations 1969
Mr. Vance R. Brown Sr. VP, Gen. Counsel & Corp. Sec. NA
Ms. Catherine Jennings VP of Global Marketing & New Bus. Devel. of Peripheral Interventions NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…